Immunomodulatory impact of α-fetoprotein.

Trends Immunol

Parker Institute for Cancer Immunotherapy (PICI), San Francisco, CA, USA; Department of Microbiology and Immunology, University of California San Francisco (UCSF), San Francisco, CA, USA. Electronic address:

Published: June 2022

α-Fetoprotein (AFP) is a fetal glycoprotein produced by most human hepatocellular carcinoma tumors. Research has focused on its immunosuppressive properties in pregnancy, autoimmunity, and cancer, and human AFP directly limits the viability and functionality of human natural killer (NK) cells, monocytes, and dendritic cells (DCs). AFP-altered DCs can promote the differentiation of naïve T cells into regulatory T cells. These properties may work to shield tumors from the immune system. Recent efforts to define the molecular characteristics of AFP identified key structural immunoregulatory domains and bioactive roles of AFP-bound ligands in immunomodulation. We propose that a key mechanism of AFP immunomodulation skews DC function through cellular metabolism. Delineating differences between fetal 'normal' AFP (nAFP) and tumor-derived AFP (tAFP) has uncovered a novel role for tAFP in altering metabolism via lipid-binding partners.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2022.04.001DOI Listing

Publication Analysis

Top Keywords

afp
6
immunomodulatory impact
4
impact α-fetoprotein
4
α-fetoprotein α-fetoprotein
4
α-fetoprotein afp
4
afp fetal
4
fetal glycoprotein
4
glycoprotein produced
4
produced human
4
human hepatocellular
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!